Patients with PF-ILD associated with acute impairment are suspected to be infectious respiratory digestive and endocrine disorders. Clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are critical to improving prognosis.
Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation. The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of PF-ILD associated with acute impairment require individual development of treatment programs, typically including pharmacotherapy, rehabilitation interventions, periodic follow-up, and other multidimensional management.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine diseases have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the acute burden of PF-ILD.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.